RFL News and Press, Rafael Holdings Inc. Class B From 02/10/21

JERUSALEM, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- LipoMedix , a clinical-stage, oncology-focused pharmaceutical company involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announced that its lea...

CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and CEO, and Timothy S. Pardee, M...

CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals , Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and Chief Executive Officer, wil...

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor Program PR Newswire NEWARK, N.J. , Dec. 22, 2020 /PRNewswire/ -- The Barer Institute, a cancer drug development initiative of Rafael...

Rafael Holdings (RFL): FQ1 GAAP EPS of -$0.09.Revenue of $1.05M (-13.2% Y/Y)Press Release For further details see: Rafael Holdings reports FQ1 results

Rafael Holdings Reports First Quarter Fiscal Year 2021 Results NEWARK, N.J. , Dec. 15, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.1 million and a loss per share of $0.09 for the first quarter of its 2021 fiscal year, the ...

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted...

The FDA has designated Fast Track status to Rafael Pharmaceuticals' ([[RFL]] +0.3%) to its lead compound, CPI-613 (devimistat), for the treatment of acute myeloid leukemia.This announcement comes on the heels of the Company receiving Fast Track designation for devimistat for the tre...

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted...

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613 ®...